128 related articles for article (PubMed ID: 23642225)
21. It takes two to tango--signalling by dimeric Raf kinases.
Baljuls A; Kholodenko BN; Kolch W
Mol Biosyst; 2013 Apr; 9(4):551-8. PubMed ID: 23212737
[TBL] [Abstract][Full Text] [Related]
22. Molecular pathways: mitogen-activated protein kinase pathway mutations and drug resistance.
Pritchard AL; Hayward NK
Clin Cancer Res; 2013 May; 19(9):2301-9. PubMed ID: 23406774
[TBL] [Abstract][Full Text] [Related]
23. Raf: a strategic target for therapeutic development against cancer.
Beeram M; Patnaik A; Rowinsky EK
J Clin Oncol; 2005 Sep; 23(27):6771-90. PubMed ID: 16170185
[TBL] [Abstract][Full Text] [Related]
24. PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types.
Britten CD
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1395-409. PubMed ID: 23443307
[TBL] [Abstract][Full Text] [Related]
25. Targeting the Raf kinases in human cancer: the Raf dimer dilemma.
Durrant DE; Morrison DK
Br J Cancer; 2018 Jan; 118(1):3-8. PubMed ID: 29235562
[TBL] [Abstract][Full Text] [Related]
26. BRAF inhibitors: From the laboratory to clinical trials.
Rahman MA; Salajegheh A; Smith RA; Lam AK
Crit Rev Oncol Hematol; 2014 Jun; 90(3):220-32. PubMed ID: 24388103
[TBL] [Abstract][Full Text] [Related]
27. Raf kinases: oncogenesis and drug discovery.
Schreck R; Rapp UR
Int J Cancer; 2006 Nov; 119(10):2261-71. PubMed ID: 16894562
[TBL] [Abstract][Full Text] [Related]
28. Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management.
Manousaridis I; Mavridou S; Goerdt S; Leverkus M; Utikal J
J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):11-8. PubMed ID: 22540151
[TBL] [Abstract][Full Text] [Related]
29. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy.
Santarpia L; Lippman SM; El-Naggar AK
Expert Opin Ther Targets; 2012 Jan; 16(1):103-19. PubMed ID: 22239440
[TBL] [Abstract][Full Text] [Related]
30. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.
Friday BB; Adjei AA
Clin Cancer Res; 2008 Jan; 14(2):342-6. PubMed ID: 18223206
[TBL] [Abstract][Full Text] [Related]
31. Targeting CRAF kinase in anti-cancer therapy: progress and opportunities.
Wang P; Laster K; Jia X; Dong Z; Liu K
Mol Cancer; 2023 Dec; 22(1):208. PubMed ID: 38111008
[TBL] [Abstract][Full Text] [Related]
32. Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease.
Zitzmann K; Rüden Jv; Brand S; Göke B; Lichtl J; Spöttl G; Auernhammer CJ
Cancer Lett; 2010 Sep; 295(1):100-9. PubMed ID: 20356670
[TBL] [Abstract][Full Text] [Related]
33. The non-linearity of RAF-MEK signaling in dendritic cells.
Riegel K; Rajalingam K
Cell Cycle; 2020 Sep; 19(18):2249-2259. PubMed ID: 32752922
[TBL] [Abstract][Full Text] [Related]
34. The role of autophagy in cytotoxicity induced by new oncogenic B-Raf inhibitor UI-152 in v-Ha-ras transformed fibroblasts.
Ahn JH; Ahn SK; Lee M
Biochem Biophys Res Commun; 2012 Jan; 417(2):857-63. PubMed ID: 22206679
[TBL] [Abstract][Full Text] [Related]
35. Potent Pan-Raf and Receptor Tyrosine Kinase Inhibitors Based on a Cyclopropyl Formamide Fragment Overcome Resistance.
Zhang Y; Wang L; Zhang Q; Zhu G; Zhang Z; Zhou X; Chen Y; Lu T; Tang W
J Chem Inf Model; 2017 Jun; 57(6):1439-1452. PubMed ID: 28485964
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of RAF dimers: it takes two to tango.
Cook FA; Cook SJ
Biochem Soc Trans; 2021 Feb; 49(1):237-251. PubMed ID: 33367512
[TBL] [Abstract][Full Text] [Related]
37. Targeting the Raf kinase cascade in cancer therapy--novel molecular targets and therapeutic strategies.
Lee JT; McCubrey JA
Expert Opin Ther Targets; 2002 Dec; 6(6):659-78. PubMed ID: 12472379
[TBL] [Abstract][Full Text] [Related]
38. Selumetinib for the treatment of cancer.
Ciombor KK; Bekaii-Saab T
Expert Opin Investig Drugs; 2015 Jan; 24(1):111-123. PubMed ID: 25385055
[TBL] [Abstract][Full Text] [Related]
39. Recent advances of RAF (rapidly accelerated fibrosarcoma) inhibitors as anti-cancer agents.
Ammar UM; Abdel-Maksoud MS; Oh CH
Eur J Med Chem; 2018 Oct; 158():144-166. PubMed ID: 30216849
[TBL] [Abstract][Full Text] [Related]
40. Protomer selectivity of type II RAF inhibitors within the RAS/RAF complex.
Vasta JD; Michaud A; Zimprich CA; Beck MT; Swiatnicki MR; Zegzouti H; Thomas MR; Wilkinson J; Crapster JA; Robers MB
Cell Chem Biol; 2023 Nov; 30(11):1354-1365.e6. PubMed ID: 37643616
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
